Literature DB >> 31709528

Highly immunosuppressive HLADRhi regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma.

Huijuan Yang1,2, Shuang Ye1,2, Shyamal Goswami3, Teng Li3, Jingwen Wu1,2, Chunmei Cao4, Jiaqiang Ma3, Bin Lu5, Xuan Pei1,2, Yanan Chen3, Jing Yu3, Huihui Xu3, Liwei Qiu3, Saifullah Afridi3,6, Libing Xiang1,2, Xiaoming Zhang3.   

Abstract

Regulatory T cells (Tregs) are crucial for the maintenance of peripheral tolerance, but they also limit beneficial responses through cancer-induced immunoediting. The roles of Treg subsets in cervical squamous cell carcinoma (CSCC) are currently unknown. Here, we aimed to perform an extensive study with an increased resolution of the Treg compartment in the peripheral blood and tumor tissues of CSCC patients. We first identified that an HLADRhi Treg population in the peripheral blood was significantly increased in CSCC patients compared to precancer patients and healthy donors. We found that HLADRhi Tregs express high levels of a panel of inhibition and activation markers and the TCR-responsive transcription factors BATF and IRF4. However, this Treg subset showed reduced calcium influx after TCR crosslinking. In addition, HLADRhi Tregs are highly proliferative and vulnerable to apoptosis. Further studies demonstrated that the HLADRhi Tregs display high levels of suppressive activity. Quantitative multiplexed immunohistochemistry revealed that an increase in the number of tumor-infiltrating HLADRhi Tregs is associated with unfavorable classical risk parameters of advanced disease stage and stromal invasion. Context-based quantification revealed that a high frequency of stromal HLADRhi Tregs in patients is significantly associated with worse progression-free survival. In the current study, we characterized a population of highly activated and immunosuppressive HLADRhi Tregs in CSCC patients. An increased HLADRhi Treg frequency may be a potential biomarker to stratify CSCC patients and evaluate therapeutic efficacies in personalized immuno-oncology studies.
© 2019 UICC.

Entities:  

Keywords:  cervical squamous cell carcinoma; immune suppression; multiplexed immunohistochemistry; progression-free survival; regulatory T cells

Mesh:

Substances:

Year:  2019        PMID: 31709528     DOI: 10.1002/ijc.32782

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia.

Authors:  Linda Hertlein; Thomas Kolben; Aurelia Vattai; Nadine Kremer; Sarah Meister; Susanne Beyer; Lucia Keilmann; Anna Hester; Mina Temelkov; Helene Heidegger; Elisa Schmoeckel; Mirjana Kessler; Sven Mahner; Udo Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-05       Impact factor: 4.553

2.  Changes in peripheral lymphocyte populations in patients with advanced/recurrent ovarian cancer undergoing splenectomy during cytoreductive surgery.

Authors:  Wei Chen; Shuang Ye; Yutuan Wu; Xuan Pei; Libing Xiang; Bo Ping; Boer Shan; Huijuan Yang
Journal:  J Ovarian Res       Date:  2021-08-30       Impact factor: 4.234

3.  Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer.

Authors:  Yu-Meng Wang; Jun-Jun Qiu; Xin-Yu Qu; Jing Peng; Chong Lu; Meng Zhang; Ming-Xing Zhang; Xing-Ling Qi; Bin Lv; Jing-Jing Guo; Chen-Yan Guo; Gui-Ling Li; Ke-Qin Hua
Journal:  Oncoimmunology       Date:  2022-02-09       Impact factor: 8.110

4.  Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation.

Authors:  Meng Wei; Yunhai Mo; Jialong Liu; Jingtong Zhai; Huilong Li; Yixin Xu; Yumeng Peng; Zhihong Tang; Tao Wei; Xiaopan Yang; Linfei Huang; Xiao Shao; Jingfei Li; Li Zhou; Hui Zhong; Congwen Wei; Qiaosheng Xie; Min Min; Feixiang Wu
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

5.  A prognostic model guides surgical resection in cervical squamous cell carcinoma.

Authors:  Baiqiang Liang; Haibing Yu; Lianfang Huang; Haiqing Luo; Xiao Zhu
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.